Department of Internal Medicine, Gachon Graduate School of Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
J Gastroenterol Hepatol. 2011 May;26(5):884-7. doi: 10.1111/j.1440-1746.2010.06611.x.
Endoscopic resection (ER) has become an important therapeutic option for early gastric cancer (EGC). Some investigators have suggested that this indication should be extended. We aimed to compare the extended indication of ER for intramucosal EGC based on data from a large, single-center study.
We assessed lymph node metastasis (LNM) status in 1721 intramucosal EGC patients who underwent surgery to evaluate the potential of extension of the ER. We investigated LNM according to Japanese extended criteria; differentiated mucosal cancers irrespective of ulcer less than 30 mm (Criteria I); differentiated mucosal cancers without ulceration irrespective of tumor size (Criteria II), undifferentiated less than 20 mm without ulceration (Criteria III). We also tried to find the groups which have no and minimal risk of lymph node metastasis.
The rate of LNM of mucosal cancer was 2.6% (45/1721). There was minimal lymph nodal metastasis risk for criteria I (0.28%, 2/726, 95% Confidence Interval [CI], 0-0.66%), and criteria II (0.23%, 2/882, 95% CI, 0-0.54%). For criteria III, there was significant lymph node metastasis risk (1.15%, 3/261, 95% CI, 0-2.44%). There was no lymph node metastasis in differentiated mucosal cancer less than 20 mm irrespective of ulcer (0%, 0/501, 95% CI 0-0.73%). The differentiated mucosal cancer group irrespective of ulcer and tumor size have a minimal risk of metastasis (0.43%, 4/941, 95% CI, 0-0.84%)
Our data support extension of the ER indication for the differentiated mucosal EGC. However, undifferentiated lesions without ulceration and smaller than 20 mm were associated with significant metastasis.
内镜下切除(ER)已成为治疗早期胃癌(EGC)的重要治疗选择。一些研究人员认为,这一适应证应该扩大。我们旨在通过一项大型单中心研究的数据来比较基于内镜下切除的黏膜内 EGC 扩大适应证。
我们评估了 1721 例接受手术评估潜在 ER 扩大适应证的黏膜内 EGC 患者的淋巴结转移(LNM)状态。我们根据日本扩展标准评估了 LNM;无溃疡的分化型黏膜癌,不论肿瘤大小(标准 I);无溃疡的分化型黏膜癌,不论肿瘤大小(标准 II),无溃疡的未分化癌<20mm(标准 III)。我们还试图找到没有和最小淋巴结转移风险的组。
黏膜癌的 LNM 率为 2.6%(45/1721)。标准 I(0.28%,2/726,95%置信区间[CI],0-0.66%)和标准 II(0.23%,2/882,95%CI,0-0.54%)的淋巴结转移风险最小。对于标准 III,有显著的淋巴结转移风险(1.15%,3/261,95%CI,0-2.44%)。无溃疡的<20mm 分化型黏膜癌无淋巴结转移(0%,0/501,95%CI,0-0.73%)。无溃疡和肿瘤大小的分化型黏膜癌组转移风险最小(0.43%,4/941,95%CI,0-0.84%)。
我们的数据支持将 ER 适应证扩大到分化型黏膜 EGC。然而,无溃疡和<20mm 的未分化病变与显著转移相关。